What's happening?

Companies that have been slow in their preparations will need to abandon the idea of customisation and stick to standardised solutions.

Many factors can result in a drug candidate failing at a phase I trial from problems with the actual medicine, such as unforeseen toxicity, or simple logistics and supply chain issues.

Drug stability testing is one of the most important parts of the drug production process. These tests aim to determine the performance of a drug under different conditions, such as humidity, sunlight and temperature, and therefore help to decide safe expiry dates.

The biggest challenge is often ensuring that limited time, effort and resources are spent developing a suitable formulation for Phase 1, and at the same time ensure that these results pave the way for further development into Phase II/III.

As the industry continues its preparations for the European Falsified Medicines Directive (FMD), Recipharm has reached another important milestone in its journey to serialisation compliance.

Antibody–drug conjugates (ADCs) are an emerging type of biotherapeutics that utilize multiple tissue specific antibodies combined with a range of linker designs to enable the transportation and selective release of cytotoxic drugs in close proximity to tumours.

ABSTRACT: The novel tyrosine kinase inhibitor AKN028 has demonstrated promising results in preclinical trials. An expedient protocol for the synthesis of the compound at kilogram scale is described, including an SNAr reaction with high regioselectivity and a Suzuki coupling. Furthermore, an efficient method for purification and removal of residual palladium is described.

At FutureLink Munich 2018, a survey regarding serialisation and the EU’s Falsified Medicines Directive (FMD) was conducted. Over 1600 responses were submitted from more than 200 pharmaceutical and healthcare executives, with many indicating that the industry is not as prepared as it should be for the new regulation.

In general, the barriers faced by Recipharm will be the same across the pharma industry, the most difficult of which being financial.

Following the EMA’s most recent survey, which concerned pharmaceutical companies’ preparedness for Brexit, it became apparent that very little guidance had been given to businesses on how best to prepare for the change.